Solid lipid nanoparticles: an oral bioavailability enhancer vehicle

Bibliography

• Speiser P. Lipid nano pellets as drug carriers for oral administration. EP0167825; 1986
   Google Scholar
• Domb AJ. Lipospheres for controlled delivery of substances. USS0188837; 1993
   Google Scholar
• Lucks JS, Muller RH. Medication vehicles made of solid lipid particles (solid lipid nanospheres - SLN). EP0605497; 1994
   Google Scholar
• Schwarz C, Mehnert W, Lucks JS, Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994;30:83-96
   Web of Science ®Google Scholar
• Muller RH, Mehnert W, Lucks JS, Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995;41:62-9
   Web of Science ®Google Scholar
• Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005;8:3-5
   Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77
   PubMed Web of Science ®Google Scholar
• Muller RH, Maassen S, Schwarz C, Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release 1997;47:261-9
   Web of Science ®Google Scholar
• Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999;47:125-32
   PubMed Web of Science ®Google Scholar
• Muller RH, Maaben S, Weyhers H, Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996;4:161-70
   PubMed Web of Science ®Google Scholar
• Wissing SA, Muller RH. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 2003;254:65-8
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and application. Adv Drug Deliv Rev 2001;47:165-96
   PubMed Web of Science ®Google Scholar
• Weiss J, Decker EA, McClements DJ, Solid lipid nanoparticles as delivery systems for bioactive food components. Food Biophys 2008;3:146-54
   Web of Science ®Google Scholar
• Yang S, Zhu J, Lu Y, Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999;16:751-7
   PubMed Web of Science ®Google Scholar
• Mei Z, Li X, Wu Q, The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharm Res 2005;51:345-51
   Google Scholar
• Shegokar R, Singh KK, Muller RH. Production & stability of stavudine solid lipid nanoparticles-From lab to industrial scale. Int J Pharm 2010; doi:10.1016/j.ijpharm.2010.08.014
   Google Scholar
• Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72
   PubMed Web of Science ®Google Scholar
• Muchow M, Maincent P, Muller RH. Lipid Nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-405
   PubMed Web of Science ®Google Scholar
• Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 2009;5:323-43
   PubMed Web of Science ®Google Scholar
• Muller RH, Runge S, Ravelli V, Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 2006;317:82-9
   PubMed Web of Science ®Google Scholar
• Xie S, Pan B, Wang M, Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine 2010;5:693-701
   PubMed Web of Science ®Google Scholar
• Zara GP, Bargoni A, Cavalli R, Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002;91:1324-33
   PubMed Web of Science ®Google Scholar
• Cavalli R, Bargoni A, Podio V, Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003;92:1085-95
   PubMed Web of Science ®Google Scholar
• Gasco MR. Methods for producing solid lipid microparticles having a narrow size distribution. USS0188837; 1993
   Google Scholar
• Yuan H, Chen J, Du Y-Z, Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B Biointerfaces 2007;58:157-64
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 2005;85:415-20
   PubMed Web of Science ®Google Scholar
• Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004;12:65-70
   PubMed Web of Science ®Google Scholar
• Florence AT. The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm Res 1997;14:259-66
   PubMed Web of Science ®Google Scholar
• Bargoni A, Cavalli R, Caputo O, Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998;15:745-50
   PubMed Web of Science ®Google Scholar
• Florence AT, Hillery AM, Hussain N, Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J Control Release 1995;36:39-46
   Web of Science ®Google Scholar
• Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991;7:71-86
   Web of Science ®Google Scholar
• Sanjula B. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 2009;17:249-56
   PubMed Web of Science ®Google Scholar
• O'Hagan DT. Intestinal translocation of particulates-implications for drug and antigen delivery. Adv Drug Deliv Rev 1990;5:265-85
   Google Scholar
• Li H, Zhao X, Ma Y, Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009;133:238-44
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Amidon GL, Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996;13:1838-45
   PubMed Web of Science ®Google Scholar
• Jepson MA, Clark MA, Foster N, Targeting to intestinal M cells. J Anat 1996;189:507
   PubMed Web of Science ®Google Scholar
• Rieux Ad, Fievez V, Garinot M, Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006;116:1-27
   PubMed Web of Science ®Google Scholar
• Goppert TM, Muller RH. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 2005;302:172-86
   PubMed Web of Science ®Google Scholar
• Jenning V, Gohla S. Comparison of wax and glyceride solid lipid nanoparticles (SLN®). Int J Pharm 2000;196:219-22
   PubMed Web of Science ®Google Scholar
• Radomska-Soukharev A. Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59:411-18
   PubMed Web of Science ®Google Scholar
• Westesen K, Bunjes H. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int J Pharm 1995;115:129-31
   Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target 2006;14:632-45
   PubMed Web of Science ®Google Scholar
• Schubert MA, Muller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm 2005;61:77-86
   PubMed Web of Science ®Google Scholar
• Vivek K, Reddy H, Murthy RSR. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 2007;8:16-24
   PubMed Web of Science ®Google Scholar
• Awad TS, Helgason T, Kristbergsson K, Temperature scanning ultrasonic velocity study of complex thermal transformations in solid lipid nanoparticles. Langmuir 2008;24:12779-84
   PubMed Web of Science ®Google Scholar
• Chen D-B, Yang T-z, Lu W-L, et al. In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing Paclitaxel. Chem Pharm Bull (Tokyo) 2001;49:1444-7
   PubMed Web of Science ®Google Scholar
• Zur Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149-55
   PubMed Web of Science ®Google Scholar
• Shastri VP, Sussman E, Jayagopal A. Functionalized solid lipid nanoparticles and methods of making and using same. USS0083781; 2006
   Google Scholar
• Vitorino C, Carvalho FA, Almeida AJ, The size of solid lipid nanoparticles: An interpretation from experimental design. Colloids Surf B Biointerfaces 2011;84:117-30
   PubMed Web of Science ®Google Scholar
• Paliwal R, Rai S, Vaidya B, Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine: NBM 2009;5:184-91
   PubMed Web of Science ®Google Scholar
• Muller RH, Ruhl D, Runge SA. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 1996;144:115-21
   Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005;107:215-28
   PubMed Web of Science ®Google Scholar
• Aji Alex MR, Chacko AJ, Jose S, Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 2011;42:11-18
   PubMed Web of Science ®Google Scholar
• Luo CF, Yuan M, Chen MS, Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm 2011;410:138-44
   PubMed Web of Science ®Google Scholar
• Suresh G, Manjunath K, Venkateswarlu V, Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007;8:162-70
   Web of Science ®Google Scholar
• Luo Y, Chen D, Ren L, Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 2006;114:53-9
   PubMed Web of Science ®Google Scholar
• Hu LD, Xing Q, Meng J, Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech 2010;11:1-6
   Google Scholar
• Hanafy A, Spahn-Langguth H, Vergnault G, Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev 2007;59:419-26
   PubMed Web of Science ®Google Scholar
• Almeida AJ, Runge S, Muller RH. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 1997;149:255-65
   Web of Science ®Google Scholar
• Jain A, Agarwal A, Majumder S, Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010;148:359-67
   PubMed Web of Science ®Google Scholar
• Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004;56:1527-35
   PubMed Web of Science ®Google Scholar
• Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 2005;27:127
   PubMed Web of Science ®Google Scholar
• Zhang N, Ping Q, Huanga G, Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006;327:153-9
   PubMed Web of Science ®Google Scholar
• Xie S, Zhu L, Dong Z, Preparation; characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces 2011;83:382-7
   PubMed Web of Science ®Google Scholar
• Ahmed El-Harati A, Charcosset C, Fessi H. Influence of the formulation for solid lipid nanoparticles prepared with a membrane contactor. Pharm Dev Technol 2006;11:153-7
   PubMed Web of Science ®Google Scholar
• Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release 2005;108:112-20
   PubMed Web of Science ®Google Scholar
• Montenegro L, Campisi A, Sarpietro MG, In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm 2011;37:737-46
   PubMed Web of Science ®Google Scholar
• Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates–A review. J Control Release 2008;128:185-99
   PubMed Web of Science ®Google Scholar
• Muller RH, Runge SA, Ravelli V, Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug–lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 2008;68:535-44
   PubMed Web of Science ®Google Scholar
• Rao KK. Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides. PCTIB2007000896; 2007
   Google Scholar